Composition:
Each Daplazole cap contains 60 mg of dexlansoprazole.
Description:
Daplazole (Dexlansoprazole) belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the (H+, K+)-ATPase at the secretory surface of the gastric parietal cell.
Indications:
Healing of Erosive Esophagitis:
Indicated in patients 12 years of age and older for healing of all grades of erosive esophagitis (EE) for up to eight weeks.
Maintenance of Healed Erosive Esophagitis and Relief of Heartburn:
Indicated in patients 12 years of age and older to maintain healing of EE and relief of heartburn for up to six months in adults and 16 weeks in patients 12 to 17 years of age.
Treatment of Symptomatic Non-Erosive Gastroesophageal Reflux Disease:
Indicated in patients 12 years of age and older for the treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.